The therapeutic prospects of using l-carnitine to manage hypertension-related organ damage

Drug Discovery Today

Volumn 15, Issue 11-12, 2010, Pages 484-492

  Mate, Alfonso ^a   Miguel Carrasco, José L ^a   Vázquez, Carmen M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARNITINE DEFICIENCY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG METABOLISM; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY INJURY; NONHUMAN; NUTRITIONAL DISORDER; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARNITINE; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION; KIDNEY DISEASES; RISK;

EID: 77954818479     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.03.014     Document Type: Review

References (72)

1. (2005) Monograph. l-carnitine. Altern. Med. Rev. 10, 42-50.
2. Arduini A., et al. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol. Ther. 2008, 120:149-156.
3. Mancia G., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009, 27:2121-2158.
4. Wolf G. The discovery of a vitamin role for carnitine: the first 50 years. J. Nutr. 2006, 136:2131-2134.
5. Vaz F.M., Wanders R.J. Carnitine biosynthesis in mammals. Biochem. J. 2002, 361:417-429.
6. Evans A.M., Fornasini G. Pharmacokinetics of l-carnitine. Clin. Pharmacokinet. 2003, 42:941-967.
7. Hedayati S.S. Dialysis-related carnitine disorder. Semin. Dial. 2006, 19:323-328.
8. Ferrari R., et al. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann. N. Y. Acad. Sci. 2004, 1033:79-91.
9. Broderick T.L. Hypocarnitinaemia induced by sodium pivalate in the rat is associated with left ventricular dysfunction and impaired energy metabolism. Drugs R. D. 2006, 7:153-161.
10. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin. Toxicol. (Phila.) 2009, 47:101-111.
11. Crill C.M., Helms R.A. The use of carnitine in pediatric nutrition. Nutr. Clin. Pract. 2007, 22:204-213.
12. Borum P.R. Carnitine in parenteral nutrition. Gastroenterology 2009, 137:S129-S134.
13. Atar D., et al. Carnitine - from cellular mechanisms to potential clinical applications in heart disease. Eur. J. Clin. Invest. 1997, 27:973-976.
14. Lango R., et al. Influence of l-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc. Res. 2001, 51:21-29.
15. Shankar S.S., et al. l-carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann. N. Y. Acad. Sci. 2004, 1033:189-197.
16. Carrero J.J., Grimble R.F. Does nutrition have a role in peripheral vascular disease?. Br. J. Nutr. 2006, 95:217-229.
17. Mynatt R.L. Carnitine and type 2 diabetes. Diabetes Metab. Res. Rev. 2009, 25(Suppl. 1):S45-S49.
18. Ruggenenti P., et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-l-carnitine therapy. Hypertension 2009, 54:567-574.
19. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a " causal" antioxidant therapy. Diabetes Care 2003, 26:1589-1596.
20. Stephens F.B., et al. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J. Physiol. 2007, 581:431-444.
21. Schreiber B.D. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif. 2006, 24:128-139.
22. Savica V., et al. Carnitine system in uremic patients: molecular and clinical aspects. Semin. Nephrol. 2004, 24:464-468.
23. Schreiber B.D. Congestive heart failure in patients with chronic kidney disease and on dialysis. Am. J. Med. Sci. 2003, 325:179-193.
24. Handelman G.J. Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. Blood Purif. 2006, 24:140-142.
25. Saper R.B., et al. Common dietary supplements for weight loss. Am. Fam. Physician 2004, 70:1731-1738.
26. Karlic H., Lohninger A. Supplementation of l-carnitine in athletes: does it make sense?. Nutrition 2004, 20:709-715.
27. Harris J.D. Fatigue in chronically ill patients. Curr. Opin. Support. Palliat. Care 2008, 2:180-186.
28. Brass E.P. Carnitine and sports medicine: use or abuse?. Ann. N. Y. Acad. Sci. 2004, 1033:67-78.
29. Peluso G., et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J. Cell. Physiol. 2000, 182:339-350.
30. Jones L.L., et al. Acylcarnitines: role in brain. Prog. Lipid Res. 2010, 49:61-75.
31. Ng C.M., et al. The role of carnitine in the male reproductive system. Ann. N. Y. Acad. Sci. 2004, 1033:177-188.
32. Sweeney J.D., Arduini A. l-carnitine and its possible role in red cell and platelet storage. Transfus. Med. Rev. 2004, 18:58-65.
33. Mancia G., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007, 25:1105-1187.
34. Rosendorff C., et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115:2761-2788.
35. Sanchez R.A., et al. Latin American guidelines on hypertension. Latin American Expert Group. J. Hypertens. 2009, 27:905-922.
36. Ogihara T., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens. Res. 2009, 32:3-107.
37. Simko F., Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J. Hypertens. 2009, 27(Suppl. 6):S1-S4.
38. Tousoulis D., et al. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 2008, 201:236-247.
39. Paravicini T.M., Touyz R.M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31(Suppl. 2):S170-S180.
40. Mathieu P., et al. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53:577-584.
41. Vaziri N.D. Causal link between oxidative stress, inflammation, and hypertension. Iran J. Kidney Dis. 2008, 2:1-10.
42. Sedeek M., et al. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr. Opin. Nephrol. Hypertens. 2009, 18:122-127.
43. Cachofeiro V., et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008, 74(Suppl. 111):S4-S9.
44. Ward N.C., Croft K.D. Hypertension and oxidative stress. Clin. Exp. Pharmacol. Physiol. 2006, 33:872-876.
45. Katusic Z.S., et al. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 2009, 30:48-54.
46. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 2009, 302:148-158.
47. San Jose G., et al. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clin. Sci. (Lond.) 2009, 116:233-240.
48. Liu J., et al. Comparison of the effects of l-carnitine and acetyl-l-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N. Y. Acad. Sci. 2004, 1033:117-131.
49. Silva-Adaya D., et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J. Neurochem. 2008, 105:677-689.
50. Famularo G., et al. Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann. N. Y. Acad. Sci. 2004, 1033:132-138.
51. Thangasamy T., et al. l-carnitine mediates protection against DNA damage in lymphocytes of aged rats. Biogerontology 2009, 10:163-172.
52. Calo L.A., et al. Antioxidant effect of l-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int. J. Cardiol. 2006, 107:54-60.
53. Calabrese V., et al. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J. Nutr. Biochem. 2006, 17:73-88.
54. Augustyniak A., Skrzydlewska E. l-carnitine in the lipid and protein protection against ethanol-induced oxidative stress. Alcohol 2009, 43:217-223.
55. Loffredo L., et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur. Heart J. 2007, 28:608-612.
56. Sharifi A.M., et al. Effect of short term treatment of l-carnitine on tissue ACE activity in streptozotocin-induced diabetic rats. Pathophysiology 2009, 16:53-56.
57. Cediel E., et al. Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R674-R681.
58. Ulker S., et al. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc. Res. 2003, 59:488-500.
59. Gomez-Amores L., et al. Antioxidant activity of propionyl-l-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci. 2006, 78:1945-1952.
60. Gomez-Amores L., et al. l-carnitine attenuates oxidative stress in hypertensive rats. J. Nutr. Biochem. 2007, 18:533-540.
61. Bueno R., et al. l-carnitine and propionyl-l-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci. 2005, 77:2082-2097.
62. Rajasekar P., et al. Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by l-carnitine: a study in the fructose-fed hypertensive rat. Clin. Exp. Hypertens. 2007, 29:517-530.
63. Miguel-Carrasco J.L., et al. l-carnitine in hypertension-related heart damage. Res. Adv. Hypertens. 2009, 1:21-38.
64. Famularo G., De Simone C. A new era for carnitine?. Immunol. Today 1995, 16:211-213.
65. Miguel-Carrasco J.L., et al. The role of inflammatory markers in the cardioprotective effect of l-carnitine in l-NAME-induced hypertension. Am. J. Hypertens. 2008, 21:1231-1237.
66. Sanz-Rosa D., et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H111-H115.
67. Chao, H.H. et al. (in press) l-carnitine attenuates angiotensin II-induced proliferation of cardiac fibroblasts: role of NADPH oxidase inhibition and decreased sphingosine-1-phosphate generation. J. Nutr. Biochem.
68. Duan S.Z., et al. PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 2009, 18:128-133.
69. Makowski L., et al. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J. 2009, 23:586-604.
70. Rauchova H., et al. The effect of chronic l-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. Eur. J. Pharmacol. 1998, 342:235-239.
71. Miguel-Carrasco J.L., et al. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur. J. Pharmacol. 2010, 632:65-72.
72. Zimmermann G.R., et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.